spacer
home > pmps > winter 2019 > a new phase of hope
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A New Phase of Hope

The global pharmaceutical industry has entered an exciting new era of drug development, bringing new hope to patients around the world. Close to 40% of all medicines in pipeline development are estimated to be biologic in nature.

The world’s top-selling commercial biologic medicines cover a broad range of diseases (including autoimmune challenges such as various forms of arthritis and psoriasis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, and other conditions such as multiple sclerosis and macular degeneration), bringing hope to many long-suffering patients.

Biologic medicines have also transformed treatment and personal care for a significant portion of the diabetes patient population. Furthermore, biologics have provided breakthrough therapies in the advanced treatment for various forms of cancer, where more than 70 new therapies have entered the market within the past five years, many of which are biologic in nature.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Justin Schroeder is Senior Executive Director of Global Marketing and Design at PCI Pharma Services, with over 20 years’ experience in outsourced pharma services in various roles, including engineering, project management, marketing, and development.
spacer
Justin Schroeder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biotechpharma to Expand Process Development and GMP Manufacturing Capacity to 5,000L

Biotechpharma UAB, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced further expansion of its fermentation capacity to 5,000L along with an additional state of the art process development laboratory, investing more than €50 million in the expansion.
More info >>

White Papers

The Process of Informed Consent (written by ACRP)

CenterWatch

Every investigator and clinical research coordinator (CRC) should recognize the importance of obtaining valid and appropriate informed consent as an important protection of the rights and welfare of human subjects. The purpose of this ACRP guidance document is not to provide a literature review or summarize the recommendations of various working groups. Instead, the Association decided it would be helpful to provide short and focused guidance which describes how to best structure the informed consent process in accordance with best practices.
More info >>

 
Industry Events

9th Annual Outsourcing in Clinical Trials Europe 2019

14-15 May 2019, Milan, Italy

Now in its 9th year, the Outsourcing in Clinical Trials Europe event is firmly established as the leading platform for the biopharmaceutical industry to collaborate to improve clinical trial partnerships, accelerate development timelines and leverage new technologies. Over 500 clinical professionals from biopharmaceutical and solution-provider companies attended the 2018 conference in Barcelona to develop new partnerships and find answers to their most pressing clinical trial challenges.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement